ID   BALL-1/CD20-KO
AC   CVCL_A8V6
SY   BINDS-24
DR   cancercelllines; CVCL_A8V6
DR   Wikidata; Q102113583
RX   PubMed=32667234;
RX   PubMed=32724441;
CC   Population: Japanese.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 7315; MS4A1.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Gly (c.842A>G); ClinVar=VCV000141141; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1075 ! BALL-1
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=32667234; DOI=10.1089/mab.2020.0015;
RA   Furusawa Y., Kaneko M.K., Kato Y.;
RT   "Establishment of an anti-CD20 monoclonal antibody (C20Mab-60) for
RT   immunohistochemical analyses.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 39:112-116(2020).
//
RX   PubMed=32724441; DOI=10.3892/ol.2020.11753;
RA   Furusawa Y., Kaneko M.K., Kato Y.;
RT   "Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for
RT   the detection of B cells.";
RL   Oncol. Lett. 20:1961-1967(2020).
//